A Possible Ban On DTC Pharma Ads Poses ‘Biggest Threat’ Of RFK Jr.’s HHS Appointment: Analyst

With Robert F. Kennedy Jr. slated to take the top spot at the U.S. Department of Health and Human Services (HHS) under President-elect Donald Trump, some in the biopharma industry are concerned about his tenure’s possible impacts on companies’ direct-to-consumer outreach.

RFK Jr. has previously expressed a desire to put a stop to DTC pharma ads in the U.S.—which is one of only two countries in the world, along with New Zealand, where prescription drugs can be directly advertised to consumers.

In just one example, while still in the presidential race earlier this year, he wrote on X (formerly Twitter), “on my first day in office I will issue an executive order banning pharmaceutical advertising on television.”

In a report Sunday, research firm Intron Health suggested that such a ban represents a major risk of RFK Jr.’s (still to-be-confirmed) HHS leadership for the biopharma industry.

“Whilst we have a relatively benign view of RFK’s impact on the Pharma industry, one thing that does worry us is the potential for the US government to ban DTC advertising of drugs,” Intron wrote, adding, “We see this as the biggest imminent threat from RFK and the new Trump administration.”

The analysts noted that because the return on investment for DTC drug ads is quite high—with “estimates ranging as high as 100%-500%, depending on the drug”—pharmas will “almost certainly” see their drug sales take a hit from a DTC ban, even as they save money on marketing spending.

Intron cited Fierce Pharma Marketing’s annual list of the top DTC ad spenders as examples of drugs that could be hardest hit by a potential ban, including AbbVie’s Skyrizi and Rinvoq, and Sanofi and Regeneron’s Dupixent, among others.

Despite RFK Jr.’s vows, without widespread support and cooperation among the industry, a ban on DTC pharma ads would likely face quite a few obstacles, primarily in terms of the right to free speech enshrined in the First Amendment of the U.S. Constitution.

Additionally, other analysts have suggested that, if confirmed as head of the HHS, RFK Jr. will likely focus more on national food and nutrition policy rather than targeting the U.S. pharmaceutical industry, where he’s criticized vaccine policies in addition to DTC practices—a habit that led to a dip in the stocks of vaccine makers following his appointment.

For the incoming administration’s potential impacts on pharma, those industry watchers say, the focus should instead be on Trump’s pick to lead the FDA. For that spot, the president-elect on Friday tapped Johns Hopkins surgeon and author Martin Makary, M.D., a vocal critic of COVID-19 public health policies and of the FDA’s Orphan Drug Act pathway for rare disease treatments.

Makary hasn’t yet shared his views on DTC pharma ads, though he did in 2013 contribute to a study analyzing certain marketing claims by healthcare providers, which ultimately concluded, “Further investigation of provider advertising, its effects on quality of care, and potential oversight mechanisms is needed.”

 

Source Link

Recommended Articles

CMS Distributes $10B To Strengthen Rural Health Care Access

The Centers for Medicare & Medicaid Services will distribute $10 billion among all 50 states during the second year of the Rural Health Transformation Program. This funding is intended to build on early progress and deliver lasting improvements in access, quality and health outcomes for rural Americans. “President Trump made a historic investment in rural ...

Read More

What Your Health Benefits Advisor Wishes You Knew Before Choosing A Plan

A family can pay their health insurance premium every month and still hesitate to see a doctor because of what the visit might cost. Or worse, an employee may believe the plan they chose through their company covers a specialist, only to learn it does not once they are at the provider’s office. Misunderstandings can ...

Read More

Feds Invite Industry To Test Electronic Prior Auth Readiness

The federal government is inviting health insurance companies, hospitals and electronic health record companies to test their readiness for upcoming electronic prior authorization requirements. The Office of the National Coordinator for Health Information Technology, the Health and Human Services Department and the Centers for Medicare and Medicaid Services announced Thursday they will hold voluntary 10-12 ...

Read More

Google Cloud Rolls Out Gemini For Healthcare

Google launched Tuesday Gemini for healthcare, an agentic artificial intelligence platform aimed at connecting complex clinical, financial and administrative workflows used by healthcare providers and payers. The platform was developed alongside clinical and health plan leaders and is built to support HIPAA compliance, the tech giant said. “The fundamental challenge in healthcare isn’t a lack ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square